5.085USD+1.29%Mkt Cap: 1.05B USDP/E: —Last update: 2026-05-26
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulati…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.05B USD
Enterprise Value1.11B USD
Revenue (TTM)—
Gross Profit-81.40M USD
Net Income (TTM)-118.84M USD
Revenue/Share—
Last Price5.085 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS8051111016
Valuation
P/E (Trailing)—
P/E (Forward)-13.96
PEG—
EV/EBITDA-8.33
EV/Revenue—
P/S—
P/B6.31
EPS (TTM)-0.56
EPS (Forward)-0.36
52W Range
1.89062% of range7.005
52W High7.005 USD
52W Low1.890 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.50%
ROA-46.89%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-101.04M USD
CapEx (TTM)22.00K USD
FCF Margin—
FCF Yield-5.49%
Net Debt-174.03M USD
Net Debt/EBITDA1.31
Balance Sheet
Debt/Equity0.15
Current Ratio13.47
Quick Ratio13.21
Book Value/Sh0.8020 USD
Cash/Share0.8050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateApr 28, 2017
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)10.81 USD
Target Range9.000 USD – 16.00 USD
# Analysts8
Ownership
Shares Out.204.93M
Float130.12M
Insiders2.63%
Institutions104.20%
Short Interest
Short Ratio21.2d
Short % Float15.77%
Short % Out.13.48%
Shares Short27.63M
Short (prev mo.)27.43M
Technical
SMA 505.298 (-4.0%)
SMA 2004.872 (+4.4%)
Beta0.28
S&P 52W Chg28.31%
Avg Vol (30d)1.21M
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—